简介:目的探讨前房注入1%利多卡因作为表面麻醉的一种辅助麻醉在眼前段内眼手术中的麻醉效果.方法对29例42眼患者眼前段内眼手术,在手术进入前房前,通过1mm前房穿刺或侧切口注入1%利多卡因,观察麻醉效果及术中术后并发症.结果Ⅰ级手术中完全无疼痛,手术配合良好;Ⅱ级术中疼痛轻微,可以耐受配合手术完成;Ⅲ级术中疼痛较剧,难以忍受.Ⅰ级者40眼,Ⅱ级者2眼,Ⅲ级者0眼,术中、术后无出现并发症.结论表面麻醉联合前房注入1%利多卡因是一种安全、有效、并发症少的麻醉方法.
简介:<正>DearSir,IamDr.Sheng-LiMi,fromtheBiomanufacturingengineeringlaboratory,GraduateSchoolatShenzhen,TsinghuaUniversity,Shenzhen,China.Iwritetopresentacasereportofnocardiabrasiliensisinapatientwithdiabetes.Nocardiaispartofagroupofaerobicactinomycetes,widelydistributedinsoil.Nocardiaasteroidsandnocardiabrasiliensisarethemostcommonhumanpathogens.Humansinfectedbynocardiaasteroidsthroughtherespiratorytractmainlysufferfromprimarysuppurativepulmonaryconditions.Infectionofnocardiabrasiliensisoftenoccursintheadvancedstagesofaprogressivediseaseorimmunedisorder,especiallyCushingsyndrome,diabetes,orinpatientsusingcorticosteroids,immunosuppressiveagentsandbroad-spectrumantibioticsforlongtime[1].Toourknowledge,thereportsofnocardiakeratitiswasveryrare
简介:目的观察在全身麻醉鼓室成形术前行手术区域利多卡因局部浸润对于术中血流动力学稳定及术后镇痛的效果。方法将60例拟在全身麻醉下行鼓室成形术的患者随机分为2组(n=30),L组在全身麻醉诱导完成后于手术区域(耳后手术切口及耳道内)行1%利多卡因混合1∶20万肾上腺素10mL多点浸润注射;N组在全身麻醉诱导完成后于手术区域行0.9%生理盐水混合1∶20万肾上腺素10mL多点浸润注射。2组患者麻醉方法相同,记录患者全身麻醉诱导完毕即刻(T1)、切皮时(T2)、耳腔成形时(T3)、出麻醉后监测治疗室(PACU)时(T4)和术后6h(T5)的平均动脉压(MAP)及心率。记录患者PACU内的苏醒时间、镇静评分(Ramesay评分),记录患者T4和T5的疼痛程度(视觉模拟评分)。结果在T2、T3及T4,L组MAP和心率显著低于N组(P〈0.05)。术后6h2组患者的MAP、心率差异无统计学意义(P值分别为0.143、0.094)。在PACU内,L组Ramesay评分高于N组(P=0.009)。T4、T5的镇痛评分L组显著低于N组(P值分别为0.0002、0.043)。结论全身麻醉鼓室成形术前行手术区域利多卡因局部浸润可明显改善围术期由于创伤应激引起的血流动力学波动,同时减轻患者术后疼痛。
简介:·Thisisacasepresentationofaverybizarreopenglobetraumawithanteriorsegmentforeignbody-fishinghookstuckinthecorneaandiris.Complicationsduetothiskindofeyetraumamightbeveryhazardousandwithseriousimpactonvisualfunction.Wearerepresentingourapproachandexperienceofthreestepmanagementofthiskindofeyeinjury:first-extracttheforeignbody,closeandreconstructtheeyeball,second-fightinflammation,andthird-restorethevisualfunctionbycataractsurgery.·
简介:AIM:Tocomparetheeffectoftopicallyadministeredandsubconjunctivallyinjectedbevacizumabonexperimentalcornealneovascularizationinratsfortwoweeksaftertreatment.METHODS:Twenty-eightSprague-Dawleyratsweredividedintofourgroupsof7animals.Eachcornealcenterofrighteyewascauterizedwithsilver/potassiumnitratefor8s.Aftercornealburning,bevacizumab(12.5mg/mL)wastopicallyadministeredthreetimesperday(TBgroup)fortwoweeksorsubconjunctivallyinjectedondays2and4aftercauterization(0.02mL;SBgroup).Asnegativecontrols,ratsreceived0.9%salinetopicallythreetimesperday(TSgroup)orsubconjunctivallyondays2and4(0.02mL;SSgroup).Digitalphotographsofthecorneaweretaken1and2weeksaftertreatmentandanalyzedtodeterminetheareaofcorneacoveredbyneovascularizationasthepercentageofcornealneovascularization.RESULTS:Oneweekaftertreatment,thepercentageofcornealneovascularizationwassignificantlylowerintheTBandSBgroupsthanintheTSandSSgroups(allP<0.05).Twoweeksaftertreatment,thepercentageofcornealneovascularizationwassignificantlylowerintheTBgroupthanintheTSgroup(P<0.05).Inallgroups,thepercentageofneovascularizationwasdecreasingastimepassed(allP<0.05)CONCLUSION:Topicallyadministeredbevacizumabhaslongerstandinganti-angiogeniceffectthansubconjunctivallyinjectedbevacizumabincornealneovascularizationfollowingchemicalinjuryinrats.